News

Crexont, an extended-release oral formulation of carbidopa and levodopa,  significantly improved sleep quality in people with Parkinson’s disease. That’s according to data based on additional analysis of the Phase 3 RISE-PD trial (NCT03670953). The results were detailed in a presentation, “Conversion to CREXONT in…

ION859, an injectable treatment being developed by Ionis Pharmaceuticals, was generally safe and well tolerated, and it reduced the levels of LRRK2 — a protein often overactive in Parkinson’s disease — even in patients without mutations in the gene that encodes it. These are data from a now-completed…

Serina Therapeutics will use $5 million in new funding to further develop SER-252 (POZ-apomorphine) as a treatment for advanced Parkinson’s disease, with a Phase 1 clinical study now expected by the end of the year. The company secured the financing from shareholders to support clinical testing of SER-252,…

Treatment for up to three years with Onapgo (apomorphine hydrochloride) — approved in the U.S. earlier this year as an add-on therapy for advanced Parkinson’s disease — significantly and sustainably reduced off time, when symptoms are not fully controlled, in adults with the neurodegenerative condition. Importantly, the researchers…

Although physical exercise has well-established benefits for people with Parkinson’s disease, too much of it may worsen fatigue and motor symptoms, according to a report of two cases in the U.K. Both patients believed that intense exercise could help them overcome the disease, including reversing the degeneration of dopaminergic…

A wearable sensor that’s designed to monitor and improve swallowing led to increased swallowing frequency for people with Parkinson’s disease in a small clinical study. The scientists believe the sensors are useful for continuous monitoring of swallowing dysfunction, or dysphagia, in Parkinson’s, and may be a way to help…

Tavapadon, an orally available small molecule being developed for Parkinson’s disease, was generally safe and eased motor symptoms within one month of being administered at either a fixed or flexible dose to adults with early-stage disease. It also reduced the risk of common side effects typically associated with similar classes…

A new study in juvenile zebra finches — a songbird species known for singing to attract mates — shows that mastering complex natural behaviors like singing depends on dopamine, a key signaling chemical that is lacking in the brains of people with Parkinson’s disease. The findings of this novel…

Vyalev (foscarbidopa and foslevodopa) demonstrated a favorable long-term safety and tolerability profile, along with sustained motor symptom control, in Parkinson’s disease patients who participated in the extension part of a Phase 3 trial (NCT03781167). Results from nearly two years of the extension study (NCT04379050) showed…

U.S. researchers have identified a novel way to block a protein known as DLK, or dual leucine-zipper kinase, that may offer a promising strategy to protect neurons from degeneration — which, the team notes, could pave the way for safer and more precise treatments for neurodegenerative conditions like Parkinson’s…